RxDoctor Payments DataLook up a doctor →

Ayaz Rahman, MD

Interventional Cardiology · Knoxville, TNNPI 1881871374

Payments from drug & device makers

$297,941in general payments, 2019–2025

Across 894 payments — averaging $333.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$140K
  • Edwards Lifesciences$118K
  • Shockwave Medical, Inc$22K
  • Medtronic$12K
  • Abbott$4K
  • Boston Scientific$2K
  • plus $975 from 11 others
$59in research payments, 2019–2025

Across 1 payment — averaging $59.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$59

What the payments were for

  • Consulting fees$50,93820%
  • Speaking & faculty fees$139,72556%
  • Travel & lodging$35,78014%
  • Food & beverage$24,22910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297,941 in reported general payments places this provider in the 90th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$237,786
Medicare patients
1,991
Services billed
4,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$49,904
XareltoRivaroxaban16$10,820
BrilintaTicagrelor16$10,705
Metoprolol Succinate27$591
Ezetimibe11$517
Carvedilol75$394
ClopidogrelClopidogrel Bisulfate61$379
Atorvastatin Calcium42$293
Isosorbide Mononitrate ErIsosorbide Mononitrate22$183
Hydrochlorothiazide23$182
Furosemide66$175
Nitroglycerin13$151
Torsemide12$138
Amlodipine Besylate22$100
Rosuvastatin Calcium17$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$10,82016 claims
AstraZenecaBrilinta$44$10,70516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →